4.4 Article

The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial

期刊

HELICOBACTER
卷 26, 期 6, 页码 -

出版社

WILEY
DOI: 10.1111/hel.12857

关键词

bacterial load; Helicobacter pylori; Lactobacillus acidophilus; Lactobacillus rhamnosus; microbiota; probiotic

资金

  1. National Taiwan University Hospital [NTUH 109-S4703, NTUH 110-S5106]
  2. Ministry of Science and Technology, Executive Yuan, ROC, Taiwan [MOST 108-2314-B-002-209, MOST 109-2314-B-002-096]
  3. Ministry of Health and Welfare [MOHW 109-TDU-B-211-114002, MOHW110-TDU-B-211-124002]
  4. Center of Precision Medicine of the Higher Education Sprout Project by the Ministry of Education [NTU-109L901401]
  5. Liver Disease Prevention & Treatment Research Foundation
  6. Taiwan Sugar Corporation

向作者/读者索取更多资源

The study found that the use of Lactobacillus acidophilus and Lactobacillus rhamnosus can reduce the bacterial load of H. pylori but does not have a significant impact on the gut microbiota composition.
Background Probiotics may alter the gut microbiota and may reduce antibiotic-related dysbiosis after H. pylori eradication. However, whether probiotics are effective in reducing the bacterial load of H. pylori and modifying the gut microbiota remains unknown. We aimed to assess the efficacy of Lactobacillus acidophilus and Lactobacillus rhamnosus in reducing the bacterial load of H. pylori and modifying the gut microbiota. Materials and methods In this double-blind, randomized, placebo-controlled trial, we recruited 40 adult subjects with moderate to high bacterial loads of H. pylori, defined as a mean delta over baseline (DOB) value of the C-13-urea breath test (C-13-UBT) of 10 or greater every 4 days 6 times. Eligible subjects were randomized in a 1:1 ratio to receive either probiotics containing Lactobacillus acidophilus and Lactobacillus rhamnosus or placebo twice daily for 4 weeks. C-13-UBT was measured weekly from the beginning of treatment to 2 weeks after treatment. Amplification of the V3 and V4 hypervariable regions of the 16S rRNA was performed for fecal microbiota. Results A total of 40 subjects were randomized to receive probiotics or placebo. The DOB value was significantly lower in the probiotic group than in the placebo group after 4 weeks of treatment (26.0 vs. 18.5, p = .045). The DOB value was significantly reduced compared to that at baseline in the probiotic group (18.5 vs. 26.7, p = .001) but not in the placebo group (26.0 vs. 25.0, p = .648). However, the eradication rate for H. pylori was 0% in both groups. There was no significant difference in the DOB values between the two groups 1 and 2 weeks after discontinuation of the probiotics. There were also no significant changes observed in the alpha-diversity and beta-diversity at week 4 compared to baseline in the probiotic group (p = .77 and 0.91) and the placebo group (p = .26 and 0.67). Conclusions Although the use of Lactobacillus acidophilus and Lactobacillus rhamnosus may reduce the bacterial load of H. pylori, there were no significant changes in the composition of gut microbiota. This trial is registered with ClinicalTrials.gov, NCT02725138.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据